[Guiding principles for the interpretation of reimbursement categories applicable in definite indications of psychiatric drugs].
Bánki
Csaba M
CM
D001714:Bipolar Disorder / Q000188:drug therapy / Q000191:economics; D052018:Bulimia Nervosa / Q000188:drug therapy / Q000191:economics; D019955:Conduct Disorder / Q000188:drug therapy / Q000191:economics; D004348:Drug Labeling / Q000331:legislation & jurisprudence; D011307:Drug Prescriptions / Q000191:economics* / Q000592:standards; D017408:Guidelines as Topic; D006801:Humans; D006814:Hungary; D007880:Legislation, Drug; D007885:Legislation, Pharmacy; D001523:Mental Disorders / Q000188:drug therapy* / Q000191:economics*; D019964:Mood Disorders / Q000188:drug therapy / Q000191:economics; D009497:Neurotic Disorders / Q000188:drug therapy / Q000191:economics; D011618:Psychotic Disorders / Q000188:drug therapy / Q000191:economics; D011619:Psychotropic Drugs / Q000191:economics* / Q000592:standards*; D012051:Reimbursement Mechanisms / Q000331:legislation & jurisprudence* / Q000592:standards; D012559:Schizophrenia / Q000188:drug therapy / Q000191:economics
D011619:Psychotropic Drugs